Skip to main content

Russia To Soon Register Second Vaccine Against COVID-19 Says Putin

By Unknown
Russia will soon register a second vaccine against COVID-19, informed President Vladimir Putin on Wednesday.

"By the way, the second vaccine against coronavirus will be registered soon," as reported by Sputnik quoting Putin while speaking to the Russian Upper House lawmakers.

On Tuesday, national consumer health watchdog said that another vaccine -- developed by the Vector research centre and dubbed as EpiVacCorona would be registered by October 15.

Putin also complimented the country's ability to counter the pathogen adding that the healthcare system is "now ready to efficiently counter' COVID-19.

"During the pandemic, we have perceived the value of every human life, the value of the heroic effort of healthcare workers, and of course, the enormous role that healthcare system's efficiency plays for the society and the country. Over the past months, its capabilities have increased significantly. The healthcare system is now ready to efficiently counter the coronavirus infection and the seasonal surge in cold-related diseases," Putin added.

In August, Russia became the first country in the world to register a vaccine against COVID-19.

As per the latest updates by Johns Hopkins University, Russia is fourth on the list with regard to most COVID-19 cases in the world -- after the US, India and Brazil -- with 1,117,487 cases and 19,720 deaths due to the pathogen

Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

Glenmark's antiviral combination for moderate Covid-19 shows no clinical benefit

By Unknown
Glenmark Pharmaceuticals Ltd on Friday said addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, the trial did not meet key end-points,  the company said. The trial's findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement , adding that favipiravir alone remains the effective choice for mild to moderate COVID-19 infection. Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while Umifenovir is licensed as a treatment for some types of flu infections in Russia and China. Fujifilm last month said a late-stage study of Avigan showed i...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more